Last reviewed · How we verify
Fosfomycin Tromethamine Granules
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme enolpyruvate transferase, preventing peptidoglycan cross-linking.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme enolpyruvate transferase, preventing peptidoglycan cross-linking. Used for Uncomplicated urinary tract infections (acute cystitis), Bacterial infections susceptible to fosfomycin.
At a glance
| Generic name | Fosfomycin Tromethamine Granules |
|---|---|
| Also known as | Monurol® |
| Sponsor | Benova (Tianjin) Innovative medicine Research Co., Ltd. |
| Drug class | Antibiotic (phosphonic acid derivative) |
| Target | MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fosfomycin is a broad-spectrum antibiotic that acts as a phosphoenolpyruvate (PEP) analog, irreversibly inhibiting MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), a key enzyme in bacterial peptidoglycan biosynthesis. This disrupts the early stages of cell wall formation, leading to bacterial cell lysis and death. The tromethamine salt formulation enhances solubility and bioavailability for oral administration.
Approved indications
- Uncomplicated urinary tract infections (acute cystitis)
- Bacterial infections susceptible to fosfomycin
Common side effects
- Diarrhea
- Nausea
- Headache
- Vaginitis
- Abdominal pain
Key clinical trials
- FOsfomycin for Male Urinary Tract Infection (PHASE3)
- Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections (PHASE3)
- Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection (PHASE3)
- EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care (PHASE3)
- Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial (PHASE4)
- Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs (PHASE3)
- Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: